Identification of proteomic signatures associated with lung cancer and COPD

Journal of Proteomics

Volumn 89, Issue , 2013, Pages 227-237

  Pastor, M D ^a   Nogal, A ^a,c   Molina Pinelo, S ^a   Melendez R ^a   Salinas, A ^a   Gonzalez De la Pena M ^a,b   Martin Juan J ^b   Corral, J ^a,b   Garcia Carbonero R ^a,b   Carnero, A ^a   Paz Ares, L ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Biomarker; Bronchoalveolar lavage; COPD; Inflammation; Lung cancer; Proteomic

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA ENOLASE; AMYLASE; AMYLASE ALPHA; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE I; CATALASE; COFILIN 1; COMPLEMENT COMPONENT C3; EZRIN; FREE RADICAL; FRUCTOSE BISPHOSPHATASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLYCOGEN PHOSPHORYLASE; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 1; LEUKOCYTE ELASTASE INHIBITOR; LIPOCORTIN 1; LIPOCORTIN 2; LIPOCORTIN 5; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEROXIREDOXIN 1; PEROXIREDOXIN 5; PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; THIOREDOXIN; TRANSKETOLASE; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION; VALIDATION PROCESS; CLINICAL TRIAL; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84880448658     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.04.037     Document Type: Article

References (67)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009, 101:554-559.
3. Yao H., Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009, 9:375-383.
4. Brody J.S., Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 2006, 3:535-537.
5. Lee G., Walser T.C., Dubinett S.M. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009, 15:303-307.
6. Hermans C., Dong P., Robin M., Jadoul M., Bernard A., Bersten A.D., et al. Determinants of serum levels of surfactant proteins A and B and Clara cell protein CC16. Biomarkers 2003, 8:461-471.
7. Indovina P., Marcelli E., Pentimalli F., Tanganelli P., Tarro G., Giordano A. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. Mass Spectrom Rev 2013, 32(2):129-142.
8. Molina-Pinelo S., Suárez R., Pastor M.D., Nogal A., Márquez-Martín E., Martín-Juan J., et al. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis Markers 2012, 32:221-230.
9. Yee J., Sadar M.D., Sin D.D., Kuzyk M., Xing L., Kondra J., et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009, 27:2787-2792.
10. Ilie M.I., Hofman V., Ortholan C., Ammadi R.E., Bonnetaud C., Havet K., et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010, 102:1627-1635.
11. Plymoth A., Yang Z., Löfdahl C.G., Ekberg-Jansson A., Dahlbäck M., Fehniger T.E., et al. Rapid proteome analysis of bronchoalveolar lavage samples of lifelong smokers and never-smokers by micro-scale liquid chromatography and mass spectrometry. Clin Chem 2006, 52:671-679.
12. Kelsen S.G., Duan X., Ji R., Perez O., Liu C., Merali S. Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. Am J Respir Cell Mol Biol 2008, 38:541-550.
13. Pinto-Plata V., Toso J., Lee K., Bilello J., Mullerova H., De Souza M., et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc 2006, 3:465-466.
14. Merkel D., Rist W., Seither P., Weith A., Lenter M.C. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5:2972-2980.
15. Casado B., Iadarola P., Pannell L.K., Luisetti M., Corsico A., Ansaldo E., et al. Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: a pilot study by CapLC-ESI-Q-TOF. J Proteome Res 2007, 6:4615-4623.
16. Hoagland L.F., Campa M.J., Gottlin E.B., Herndon J.E., Patz E.F. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 2007, 110:2260-2268.
17. Jessie K., Pang W.W., Haji Z., Rahim A., Hashim O.H. Proteomic analysis of whole human saliva detects enhanced expression of interleukin-1 receptor antagonist, thioredoxin and lipocalin-1 in cigarette smokers compared to non-smokers. Int J Mol Sci 2010, 11:4488-4505.
18. Brower V. Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 2009, 101:11-13.
19. Kang S.M., Sung H.J., Ahn J.M., Park J.Y., Lee S.Y., Park C.S., et al. The haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst 2011, 7:1167-1175.
20. Tian T., Hao J., Xu A., Hao J., Luo C., Liu C., et al. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 2007, 98:1265-1274.
21. Garcia M., Derocq D., Pujol P., Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990, 5:1809-1814.
22. Kim H., Kang H.J., You K.T., Kim S.H., Lee K.Y., Kim T.I., et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006, 6:3466-3476.
23. Zeng H., Xu L., Xiao D., Zhang H., Wu X., Zheng R., et al. Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem 2006, 54:889-896.
24. Zhang X.Q., Chen G.P., Wu T., Yan J.P., Zhou J.Y. Expression and clinical significance of ezrin in non-small-cell lung cancer. Clin Lung Cancer 2012, 13:196-204.
25. Chen G., Wang H., Miller C.T., Thomas D.G., Gharib T.G., Misek D.E., et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 2004, 202:321-329.
26. Wang Z., Zhao X. Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes. Zhonghua Jie He He Hu Xi Za Zhi 1998, 21:164-166.
27. Muzio G., Maggiora M., Paiuzzi E., Oraldi M., Canuto R.A. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 2012, 52:735-746.
28. Kang M.W., Lee E.S., Yoon S.Y., Jo J., Lee J., Kim H.K., et al. AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res 2011, 39:78-85.
29. Li C.P., Goto A., Watanabe A., Murata K., Ota S., Niki T., et al. AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 2008, 204:295-304.
30. Tang X.H., Gudas L.J. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011, 6:345-364.
31. Ruiz F.X., Gallego O., Ardèvol A., Moro A., Domínguez M., Alvarez S., et al. Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact 2009, 178:171-177.
32. Matsunaga T., Wada Y., Endo S., Soda M., El-Kabbani O., Hara A. Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers. Front Pharmacol 2012, 3:5.
33. Eigenbrodt E., Kallinowski F., Ott M., Mazurek S., Vaupel P. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res 1998, 18:3267-3274.
34. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
35. Volm M., Mattern J., Stammler G. Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res 1995, 15:2607-2609.
36. Hacker S., Lambers C., Hoetzenecker K., Pollreisz A., Aigner C., Lichtenauer M., et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab 2009, 55:31-40.
37. Yoshihara T., Kadota Y., Yoshimura Y., Tatano Y., Takeuchi N., Okitsu H., et al. Proteomic alteration in gastic adenocarcinomas from Japanese patients. Mol Cancer 2006, 5:75.
38. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Yu C.Y., et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005, 4:2062-2069.
39. Jazii F.R., Najafi Z., Malekzadeh R., Conrads T.P., Ziaee A.A., Abnet C., et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006, 12:7104-7112.
40. Allal A.S., Kähne T., Reverdin A.K., Lippert H., Schlegel W., Reymond M.A. Radioresistance-related proteins in rectal cancer. Proteomics 2004, 4:2261-2269.
41. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 2007, 16:497-506.
42. Castagna A., Antonioli P., Astner H., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
43. Bottoni P., Giardina B., Scatena R. Proteomic profiling of heat shock proteins: an emerging molecular approach with direct pathophysiological and clinical implications. Proteomics Clin Appl 2009, 3:636-653.
44. Potter C.P., Harris A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003, 89:2-7.
45. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
46. Chotirat S., Thongnoppakhun W., Promsuwicha O., Boonthimat C., Auewarakul C.U. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol 2012, 5:5.
47. Tan F., Jiang Y., Sun N., Chen Z., Lv Y., Shao K., et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics 2012, 11. [M111 008821].
48. Yu G.P., Chen G.Q., Wu S., Shen K., Ji Y. The expression of PEBP4 protein in lung squamous cell carcinoma. Tumour Biol 2011, 32:1257-1263.
49. Yu G.P., Huang B., Chen G.Q., Wu S., Ji Y., Shen Z.Y. PEBP4 gene expression and its significance in invasion and metastasis of non-small cell lung cancer. Tumour Biol 2012, 33:223-228.
50. Liu H., Kong Q., Li B., He Y., Li P., Jia B. Expression of PEBP4 protein correlates with the invasion and metastasis of colorectal cancer. Tumour Biol 2012, 33:267-273.
51. Comandini A., Marzano V., Curradi G., Federici G., Urbani A., Saltini C. Markers of anti-oxidant response in tobacco smoke exposed subjects: a data-mining review. Pulm Pharmacol Ther 2010, 23:482-492.
52. Alexandre B.M., Charro N., Blonder J., Lopes C., Azevedo P., Bugalho de Almeida A., et al. Profiling the erythrocyte membrane proteome isolated from patients diagnosed with chronic obstructive pulmonary disease. J Proteomics 2012, 76 Spec No:259-269. (Epub 2012 Apr 17). 10.1016/j.jprot.2012.04.008.
53. Bandow J.E., Baker J.D., Berth M., Painter C., Sepulveda O.J., Clark K.A., et al. Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies-COPD biomarker discovery study. Proteomics 2008, 8:3030-3041.
54. Pierrou S., Broberg P., O'Donnell R.A., Pawłowski K., Virtala R., Lindqvist E., et al. Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:577-586.
55. Kim J.H., Bogner P.N., Ramnath N., Park Y., Yu J., Park Y.M. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res 2007, 13:3875-3882.
56. Lehtonen S.T., Svensk A.M., Soini Y., Pääkkö P., Hirvikoski P., Kang S.W., et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004, 111:514-521.
57. Alfonso P., Catalá M., Rico-Morales M.L., Durante-Rodríguez G., Moro-Rodríguez E., Fernández-García H., et al. Proteomic analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue. Proteomics 2004, 4:442-447.
58. Wong K.K., Jacks T., Dranoff G. NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila) 2010, 3:403-405.
59. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002, 20:556-563.
60. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5:297-309.
61. Cheng Q., Lee H.H., Li Y., Parks T.P., Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000, 19:4936-4940.
62. Denlinger C.E., Rundall B.K., Jones D.R. Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg 2004, 16:28-39.
63. Shen H.M., Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
64. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005, 65:6934-6942.
65. Osaki S., Nakanishi Y., Takayama K., Pei X.H., Ueno H., Hara N. Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J Exp Clin Cancer Res 2003, 22:69-75.
66. Chen W., Wang X., Bai L., et al. Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J Cell Biochem 2008, 105:554-561.
67. Jones D.R., Broad R.M., Madrid L.V., et al. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 2000, 70:930-936. [discussion 936-937].